The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1534-6269

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) ; volume:23 ; number:11 ; day:27 ; month:8 ; year:2021 ; pages:1-15 ; date:11.2021
Current oncology reports ; 23, Heft 11 (27.8.2021), 1-15, 11.2021

Creator: De Giglio, Andrea
Di Federico, Alessandro
Nuvola, Giacomo
Deiana, Chiara
Gelsomino, Francesco

Contributor: SpringerLink (Online service)

DOI: 10.1007/s11912-021-01124-9

URN: urn:nbn:de:101:1-2022012305445895792043

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.06.0008, 1:03 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

De Giglio, Andrea
Di Federico, Alessandro
Nuvola, Giacomo
Deiana, Chiara
Gelsomino, Francesco
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

Related objects

Reset password